The 2022 Health for Humanity Report, which acts as Johnson & Johnson’s yearly disclosure on environmental, social, and governance (ESG) performance, was released today. The Report details developments in relation to our challenging set of Health for Humanity 2025 Goals.
In 2022, we kept our attention on the difficult global health problems that matched our ESG strategic targets. These strategic priorities—promoting global health justice, empowering our employees, and advancing environmental health—are built on a foundation of responsibility and innovation and direct how we work to create value for the stakeholders we serve.
Promoting equity in health worldwide
By assisting in the transformation of the future of global health care access, we work for a healthier, more equitable future. dispensed our medication SIRTURO (bedaquiline), which is used to treat multidrug-resistant tuberculosis, for more than 586,000 courses since 2014. ranked second in the 2022 Access to Medicine Index, demonstrating the success of our plan to make our technology and medicines accessible to individuals in low- and middle-income nations.
achieved our Health for Humanity Goal by providing 1.3 million nurses, midwives, and community health workers with the knowledge, resources, and growth they need through the Johnson & Johnson Center for Health Worker Innovation, including initiatives funded by the Johnson & Johnson Foundation.
Empowering our staff
By building a company that is prepared for the future and encouraging employees to contribute their talents and knowledge to building healthy communities throughout the world, we hope to attract and retain top talent. Achieved our Health for Humanity 2025 Goal of 36% ethnic/racial diversity in managerial positions inside the United States. Our Credo Survey received responses from more than 130,000 workers (92%) and had an 87% favorability rating, which is evidence of our values-driven culture. formally introduced J&J Learn, a dynamic learning and development environment that offers staff members ongoing chances for development, reskilling, and upskilling.
Environmental Health Advancement
In order to support a healthy planet, we push environmental health objectives. We achieved the milestone of using only renewable energy for all of our activities in Europe, and we have a direct power purchase agreement in place that will provide us with 100% renewable energy beginning in 2023 for all of our operations in Brazil. Listed on the CDP A List for climate leadership for the fifth consecutive year. launched a new multiyear collaborative project called Digital Health in a Circular Economy (DiCE) to reduce digital health waste, with co-funding from the EU Horizon Europe program.
Leading through innovation and responsibility
Across the value chain, we are dedicated to compliance, integrity, and decision-making that is supported by science and data. We have spent $14.6 billion on R&D across all of our businesses.
Updated Responsibility Standards for Suppliers with higher demands for respecting and advancing human rights throughout our operations and business. These standards now include greater expectations for information security, environmental responsibility, diversity, equity, and inclusion.
Frameworks and Standards for Reporting
The Global Reporting Initiative (GRI) Standards were followed in the creation of the Health for Humanity Report for 2022. We also report on how we performed in relation to additional ESG guidelines and standards (see ESG Disclosure Index), such as: Relevant Standards from the Sustainability Accounting Standards Board (SASB): Building on our responses to the CDP climate change questionnaire, the HC-BP, HC-MS, and CG-HP Task Force on Climate-related Financial Disclosures (TCFD) has added disclosures against this set of 17 indicators to Norges Bank Investment Management’s and Basel Institute on Governance’s reporting framework. UN Global Compact (UNGC) view our yearly Progress Communication.
Environmental, Social, and Governance (ESG) at Johnson & Johnson
We are motivated by Our Purpose, which is to alter the course of human health. Our ESG approach, which is built on a foundation of accountability and innovation, concentrates our efforts on the areas where we are uniquely positioned to make the biggest difference, including advocating global health equity, empowering our workers, and advancing environmental health. By fostering rewarding opportunities for our employees and suppliers, protecting and enhancing the communities in which we live and work, and delivering profitable, sustainable growth for investors, we build long-term value. Our Health for Humanity 2025 Goals complement 11 of the 17 Sustainable Development Goals of the United Nations and are how we hold ourselves publicly accountable. They also correlate with our ESG approach.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details Click here
For more Pharma related updates Click here